Enoxaparin Sodium Injection Articles

Novartis admits looking at Aventis, but Sanofi defends its bid for the latter

22 March 2004

Aventis highlights its late-stage pipeline to justify its stand-alone strategy

16 February 2004

Aventis reports robust results for 2003 and cements its stand-alone position

16 February 2004

Profits up at Aventis in 3rd quarter, but full-year sales forecasts lowered

10 November 2003

Aventis opts out of Lovenox suit

8 September 2003

Aventis moves to head off Lovenox threat

11 August 2003

Aventis on target as performance picks up

4 August 2003

Stock Commentary - Europe

7 July 2003

Thrombosis market- significant revenue opportunity; Morgan Stanley report

7 July 2003

Teva joins Amphastar in going for generic version of Aventis' Lovenox

7 July 2003

$1.1 bill buyback at Aventis as profits fall

5 May 2003

Stock Commentary - Europe

21 April 2003

Aventis confirms FDA error in generic "mis-alert"

21 April 2003

Stock Commentary - Europe

14 April 2003

FDA mis-alert on generic Lovenox gives Aventis shares a bad ride

14 April 2003

Fast-track review for Arixtra sNDA in USA

10 March 2003

Aventis sued for alleged US anticoagulant monopoly

10 March 2003

Aventis 2002 results in line with expectations, but firm cuts 2003 forecast

10 February 2003

Aventis' EPS leaps 29% in 2nd quarter, blockbusters power growth

5 August 2002

Aventis says seven of its products will be blockbusters by 2006

24 June 2002

Update: Aventis says seven of its products will be blockbusters by

24 June 2002

Emisphere hit by failure of oral heparin in Phase III

27 May 2002

Aventis blockbusters driving growth

6 May 2002

Lovenox plus Integrilin have role in ACS

1 April 2002

Aventis starts large-scale VTE trial of Clexane

25 March 2002

Aventis posts 39% rise in core business net income, exceeding its own targets

18 February 2002

Update: Akzo and Sanofi-Synthelabo's Arixtra debuts in USA for DVT

18 February 2002

Akzo and Sanofi-Synthelabo's Arixtra debuts in USA for DVT prevention

18 February 2002

New antithrombotic Arixtra cleared in USA

13 December 2001

Arixtra "at least as good" as LMWH in angina

15 November 2001

Aventis growth driven by strong US pharmaceutical sales

6 November 2001

Arixtra studies support superiority to LMWH

5 November 2001

Aventis still confident about hitting 35% earnings rise for 2001

27 September 2001

ASSENT 3 trial shows new regimen benefit

24 August 2001

Sanofi-Synthelabo and Akzo Nobel's Arixtra is approvable, says FDA

16 August 2001

US pharmaceutical sales driving growth at Aventis as 2nd-qtr profits rise

2 August 2001

Arixtra tops LMWH in meta-analysis

11 July 2001

AstraZeneca's novel anticoagulant Exanta shows promise in DVT trials

11 July 2001

Preventing DVT avoids long-term complications, costs

10 July 2001

Aventis says strategy for growth is working at R&D presentation

16 May 2001

US pharmaceutical sales driving growth at Aventis as profits leap 82%

10 May 2001

New combo therapies will take center stage in AMI, says DR

21 March 2001

Massive hike in net income for Aventis in 2000 as focus is firmly placed on

2 March 2001

Ph II data with AstraZeneca thrombin inhibitor

6 December 2000

FDA backs Lovenox for seventh indication

22 November 2000

SkyePharma wins FDA approval for Solaraze

25 October 2000

Akzo Nobel seeks shift in perception from chemicals to pharma, discloses

5 October 2000

First pentasaccharide data revealed

7 September 2000

UPDATE - Guerin's role in Sanofi-Synthelabo terminated; earnings rise 58%

7 September 2000

NICE-3 shows combination role for LMWH and antiplatelet agents

6 September 2000

Sanofi-Synthelabo's pentasaccharide shows superiority over Lovenox

31 August 2000

Stock Commentary Europe

31 August 2000

Aventis focuses on US market, from which it now gains just 25% of turnover

17 August 2000

Strong first-half pharma sales for Aventis, fuelled by 40% growth in the US

28 July 2000

Upbeat presentations marks Goldman Sachs' health care conference

20 June 2000

Aventis net income climbs 63% in 1st qtr

23 May 2000

First disclosure of Aventis' early-stage R&D pipeline

23 May 2000

Analysts explore the antithrombotic arena, optimism for new therapies

17 May 2000

Pharma sales push Aventis' turnover up

3 May 2000

Aventis 1999 net loss hits 970 million euros, though pharma income rises 19%

23 March 2000

Genentech unveils new trials for tenecteplase

15 March 2000

Aventis sales rise 4.2% in 1999

3 February 2000

Aventis undervalued, say analysts, who forecast rising profitability

6 January 2000

Rhone-Poulenc sales flat for third quarter

8 November 1999

R-PR's Lovenox, efficacy in venous thromboembolism

16 September 1999

Sanofi-Synthelabo looks to USA for further growth, confident about pipeline

7 September 1999

R-P's net income plunges 82%

28 July 1999

World market for thrombosis drugs "set to grow 37% in 1998-2005"

27 July 1999

R-PR opens $50 mill plant in Singapore

21 July 1999

DuPont files for new LMWH in USA (updated)

6 July 1999

More Euro pharma firms discuss plans for future growth at GS conference

24 June 1999

Euro pharma firms spell out plans for future growth to US investors

17 June 1999

Fragmin cleared for angina in USA

3 June 1999

Rhone-Poulenc's oncology products drive growth, doubts emerge over Aventis

6 May 1999

"Sound set" of results for Hoechst in 1998, double-digit drug growth

29 March 1999

Strong sales growth for Rhone-Poulenc in the USA, merger with Hoechst on

4 February 1999

Aventis Pipeline Rich In Near-Term Prospects

10 December 1998

Hoechst & Rhone-Poulenc Merge To Create Aventis

1 December 1998

TIMI 11B Reinforces Enoxaparin Role In UA

18 November 1998

Hoechst/Rhone-Poulenc Merger Looks More Likely

17 November 1998

Rhone-Poulenc Net Income Rises 8% For 3rd Qtr

30 October 1998

R-PR Drops Klerval From Development

16 October 1998

Second-Quarter Earnings Up 29% At Rhone-Poulenc

30 July 1998

R-PR Licenses Novartis' Revasc

30 June 1998

Rhone-Poulenc Rorer Cuts More Jobs

25 June 1998

Double-Digit Pharma Sales Growth Boosts Rhone-Poulenc

29 April 1998

R-PR Expanding Lovenox Production

16 April 1998

Integrilin "Approvable" In USA For Unstable Angina

8 April 1998

R-PR's Lovenox Cleared In USA For Angina

31 March 1998

New Indication For R-PR's Lovenox

5 February 1998

High Hopes For New Products At Rhone-Poulenc

5 February 1998

More Approvals For Lovenox In Angina

14 January 1998

Rhone-Poulenc 3rd Qtr Net Income Up 38.8%

31 October 1997

Enoxaparin Approved For Angina And MI

25 September 1997

R-PR Accused Of Promoting Off-Label Drug Use

18 September 1997

COR Therapeutics Boosted By Integrilin Data

28 August 1997

Centeon Impact Still Hitting R-PR Results

29 July 1997

FDA Advisory C'tee Recommendation For R-PR's Lovenox

3 July 1997

Rhone-Poulenc Rorer Expands In Singapore

19 May 1997

R-PR Files To Market Lovenox For Angina

20 March 1997

Showing 101-200 of 236 articles

Go to beginningPreviousNextGo to end